News | September 17, 2024
Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Also received tentative approval for 137 mg
Subscribe To Our Newsletter & Stay Updated
